Navigation Links
SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition
Date:12/6/2007

mal BCR-ABL tyrosine kinase, which results from a characteristic chromosome abnormality (also known as the Philadelphia chromosome) that causes chronic myelogenous leukemia or CML, a cancer of the bone marrow. SGX393 has shown both potent in vitro blockade of the activity of BCR-ABL and in vivo activity against human leukemic cells that depend on BCR-ABL for their uncontrolled growth and proliferation. In addition, SGX393 has shown potent activity against a broad spectrum of mutant forms of BCR-ABL that render this cancer target resistant to imatinib (Gleevec (R)), the current standard of care for CML. One of the key drug resistant forms of BCR-ABL inhibited by SGX393 is the T315I mutation, which is also resistant to the two second-generation BCR-ABL inhibitors, nilotinib (Tasigna (R)) and dasatinib (Sprycel (R)). In addition, SGX is engaged in a strategic collaboration with Novartis that aims to discover and develop next generation BCR-ABL inhibitors for treatment of newly-diagnosed CML patients.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST(TM) drug discovery platform, such as next generation BCR-ABL inhibitors being developed by SGX and in partnership with Novartis and cMET tyrosine kinase inhibitors, including SGX523, and JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Forward-looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, research and development programs, the potential of SGX's BCR-ABL inhibitors as treatments for chron
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Falls Church, VA (PRWEB) May 29, 2015 ... Requirements, Best Practices and Innovative Approaches, **FDAnews Webinar**, ... p.m. EDT, http://www.fdanews.com/MDCybersecurityQA , Network connectivity ... devices, but it also exposes a minefield of ... condition to healthcare professionals, but can manufacturers be ...
(Date:5/28/2015)... On Monday, June 1, KORT, The Best in Rehab, ... Shelbyville, Kentucky . Clinic Director, Chad Flickinger, PT, MPT, CES, ... , “ Shelbyville is a growing community and KORT ... better serve the residents of Shelby County. At KORT, we ... possible by providing accessible and immediate care in a very ...
(Date:5/28/2015)... 29, 2015 Recently, KORT Richmond, 5006 Atwood ... regain their quality of life. The program works with those ... one for years, but are still having difficulty. , According ... million people living with limb loss in the United States. ... including diabetes and peripheral arterial disease – trauma (45%) and ...
(Date:5/28/2015)... Calgary, AB (PRWEB) May 28, 2015 ... the world and all over the United States. There ... of heart disease, who can experience symptoms of angina ... cardiac medications, heart stents and/or bypass surgery. , “No ... angina due to coronary artery disease that is considered ...
(Date:5/28/2015)... May 28, 2015 Cosmetic Town Journal ... surgeons and patients alike. You can find information on ... and body contouring. Readers can directly connect to the ... experience from the ground up. , The continued addition ... the community to grow and getting it closer to ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Medical Device Cybersecurity Quality Assurance: Requirements, Best Practices and Innovative Approaches Webinar, June 23, 2015 2Health News:FDAnews Announces — Medical Device Cybersecurity Quality Assurance: Requirements, Best Practices and Innovative Approaches Webinar, June 23, 2015 3Health News:KORT Physical Therapy Opens New Clinic In Shelbyville, Kentucky 2Health News:KORT Physical Therapy Opens New Clinic In Shelbyville, Kentucky 3Health News:KORT Richmond Physical Therapy Adds New Program to Help Amputees 2Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2Health News:New York Cosmetic Doctors Now in Cosmetic Town 2Health News:New York Cosmetic Doctors Now in Cosmetic Town 3
... hearing loss in laboratory animals, according to two new ... of a pill that could stave off noise-induced and ... findings will be reported Wednesday at the Association for ... author Colleen Le Prell, Ph.D., a researcher at the ...
... National Head Start Association (NHSA) issued the following statement ... is the director of the Albina Head Start program ... be created -- and more than 200,000 existing jobs ... has signed into law the economic recovery package containing ...
... Quarterly EPS of $0.39, Total Revenues of $109.1 Million ... Total Revenues by 17% -- Company Generates $178.3 Million ... Gen-Probe Incorporated (Nasdaq: GPRO ... quarter and full year ended December 31, 2008, including ...
... MADISON, Wis., Feb. 17 /PRNewswire-FirstCall/ -- Cogdell ... appointment of Roger Herritz as President of the Midwest ... Inpatient Project Delivery for the Company,s wholly owned subsidiary, ... the Company,s Madison office, Mr. Herritz will be responsible ...
... Lingering physical effects of cancer a likely cause, finds study, ... fighting cancer wasn,t hard enough, a new Dutch study concludes ... be able to find a job. , The meta-analysis of ... those who,d battled cancer were out of work vs. 15.2 ...
... sent today to,President Obama and members of the ... leadership of Congress on the enactment of,the American ... the first time,provides financial incentives to physicians who ... improve both the quality and cost-,effectiveness of patient ...
Cached Medicine News:Health News:Vitamin supplements may protect against noise-induced hearing loss 2Health News:Vitamin supplements may protect against noise-induced hearing loss 3Health News:NHSA: President Obama, Congress Deserve High Praise for $2.1 Billion in Recovery Package for Head Start 2Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 2Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 3Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 4Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 5Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 6Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 7Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 8Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 9Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 10Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 11Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 12Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 13Health News:Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 14Health News:Cogdell Spencer Names Herritz and Wolters to Key Leadership Positions Within Erdman 2Health News:Cogdell Spencer Names Herritz and Wolters to Key Leadership Positions Within Erdman 3Health News:Cogdell Spencer Names Herritz and Wolters to Key Leadership Positions Within Erdman 4Health News:One in Three Cancer Survivors on Unemployment Line 2Health News:One in Three Cancer Survivors on Unemployment Line 3Health News:Allscripts Applauds Economic Stimulus Incentives Rewarding Physicians for Using Electronic Health Records 2Health News:Allscripts Applauds Economic Stimulus Incentives Rewarding Physicians for Using Electronic Health Records 3Health News:Allscripts Applauds Economic Stimulus Incentives Rewarding Physicians for Using Electronic Health Records 4Health News:Allscripts Applauds Economic Stimulus Incentives Rewarding Physicians for Using Electronic Health Records 5Health News:Allscripts Applauds Economic Stimulus Incentives Rewarding Physicians for Using Electronic Health Records 6
(Date:5/28/2015)... May 28, 2015  Eli Lilly and Company (NYSE: ... announced cash tender offer for up to $1.6 billion aggregate ... Holders of notes who tendered, and did not validly ... New York City time, on May 27, 2015 ... by Lilly, are eligible to receive the total consideration. The ...
(Date:5/28/2015)... , May 28, 2015 Zimmer Holdings, ... it has finalized agreements with buyers to divest in ... Unicompartmental High-Flex Knee System assets, Biomet Discovery® Elbow System ... are in furtherance of Zimmer,s pending acquisition of Biomet, ... Zimmer continues to work constructively with the Bureau of ...
(Date:5/28/2015)... , May 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ... for the second quarter and three and six months ended ... Canadian dollars and in accordance with International Financial Reporting Standards ... recorded a net loss of $5.9 million ($0.35 per common ... compared to a net loss of $0.4 million ($0.03 per ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... - Results Presented at Endocrine Society,s 90th Annual ... June 16 ,Bionovo Inc. (Nasdaq: BNVI ) ... elements important in developing drugs for breast cancer ... Endocrine Society,s,90th Annual Meeting, showed that the new ...
... Metabolex, Inc., a,biopharmaceutical company focused on the ... treatment of metabolic diseases,announced today that it has ... MBX-8025 in overweight or obese patients with high ... designed to assess the drug,s,effect on dyslipidemia and ...
Cached Medicine Technology:Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs 2Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs 3Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
... The Seal-Away CS and Alliance ... designed for the introduction of ... coronary sinus from a superior ... Jude Medical's outstanding peel-away introducer ...
The AXIUS™ Blower/Mister provides controlled delivery of CO2 and saline to improve visibility during anastomosis....
... DYNALINK .018 Biliary Self-Expanding Stent System combines low-profile, ... system. This .018" guide wire compatible stent system ... in all diameters (5.0 - 10.0 mm). Now, ... is offered in five stent lengths (28, 38, ...
... Response catheters comprise the world's broadest ... electrophysiology procedures. Their advanced catheter design ... torque response with a soft, atraumatic ... French sizes, Supreme and Response catheters ...
Medicine Products: